Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy.
Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical …